AKT1 and Other metabolic disease: Although most compounds targeting the PI3K/Akt pathway – such as estrogen [114], resveratrol, curcumin [115], GDC-0941, duvelisib, and leniolisib [112] – have already entered clinical trials for other diseases (oncology, metabolic disorders, and neurodegenerative diseases), their clinical application in sepsis, especially SAE, remains largely unexplored or is still in its infancy.